{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:21:11Z","timestamp":1761060071318},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T00:00:00Z","timestamp":1453852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12288-016-0647-1","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T02:03:18Z","timestamp":1453860198000},"page":"22-30","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Once-Weekly 1.6\u00a0mg\/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Yong","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-yun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-fang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-ju","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"issue":"11","key":"647_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046\u20131060","journal-title":"N Engl J Med"},{"issue":"1","key":"647_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"13","key":"647_CR3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, Rosinol L, Hussein M et al (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26(13):2171\u20132177","journal-title":"J Clin Oncol"},{"issue":"13","key":"647_CR4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R et al (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28(13):2259\u20132266","journal-title":"J Clin Oncol"},{"issue":"10","key":"647_CR5","first-page":"999","volume":"89","author":"RS Vincent","year":"2014","unstructured":"Vincent RS (2014) Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999\u20131009","journal-title":"Am J Hematol"},{"issue":"7","key":"647_CR6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS et al (2014) Clinical profiles of multiple myeloma in Asia\u2014an Asian Myeloma Network study. Am J Hematol 89(7):751\u2013756","journal-title":"Am J Hematol"},{"issue":"1","key":"647_CR7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E (2010) Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 46(1):160\u2013169","journal-title":"Eur J Cancer"},{"issue":"24","key":"647_CR8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32(24):2531\u20132540","journal-title":"J Clin Oncol"},{"issue":"6","key":"647_CR9","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","volume":"28","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28(6):1346\u20131348","journal-title":"Leukemia"},{"issue":"6","key":"647_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San MJF et al (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587\u2013600","journal-title":"J Clin Oncol"},{"issue":"13","key":"647_CR11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV et al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125(13):2068\u20132074","journal-title":"Blood"},{"issue":"17","key":"647_CR12","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519\u20134529","journal-title":"Blood"},{"issue":"6","key":"647_CR13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S et al (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98(6):980\u2013987","journal-title":"Haematologica"},{"issue":"5","key":"647_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"5","key":"647_CR15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.12070","volume":"90","author":"S Moore","year":"2013","unstructured":"Moore S, Atwal S, Sachchithanantham S et al (2013) Weekly intravenous bortezomib is effective and well tolerated in relapsed\/refractory myeloma. Eur J Haematol 90(5):420\u2013425","journal-title":"Eur J Haematol"},{"issue":"4","key":"647_CR16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","volume":"118","author":"DE Reece","year":"2011","unstructured":"Reece DE, Hegenbart U, Sanchorawala V et al (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study. Blood 118(4):865\u2013873","journal-title":"Blood"},{"issue":"10","key":"647_CR17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11(10):934\u2013941","journal-title":"Lancet Oncol"},{"issue":"7","key":"647_CR18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V et al (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23(7):1337\u20131341","journal-title":"Leukemia"},{"issue":"2","key":"647_CR19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, Viterbo L, Greil R et al (2013) Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 31(2):247\u2013255","journal-title":"J Clin Oncol"},{"issue":"1","key":"647_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3\u20139","journal-title":"Leukemia"},{"issue":"15","key":"647_CR21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San MJ, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420","journal-title":"J Clin Oncol"},{"issue":"5","key":"647_CR22","doi-asserted-by":"crossref","first-page":"dju067","DOI":"10.1093\/jnci\/dju067","volume":"106","author":"SA Tuchman","year":"2014","unstructured":"Tuchman SA, Shapiro GR, Ershler WB et al (2014) Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst 106(5):dju067","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"647_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040620712440589","volume":"3","author":"M Sopena","year":"2012","unstructured":"Sopena M, Clavero EM, Villa P, Martinez-Lopez J (2012) Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma. Ther Adv Hematol 3(3):147\u2013154","journal-title":"Ther Adv Hematol"},{"issue":"19","key":"647_CR24","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375\u20134382","journal-title":"Blood"},{"issue":"2","key":"647_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00432-013-1570-6","volume":"140","author":"BT Huang","year":"2014","unstructured":"Huang BT, Tan Y, Zhao WH, Zeng QC, Li BS, Chen RL (2014) How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. J Cancer Res Clin Oncol 140(2):303\u2013309","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"647_CR26","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","volume":"115","author":"CB Reeder","year":"2010","unstructured":"Reeder CB, Reece DE, Kukreti V et al (2010) Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115(16):3416\u20133417","journal-title":"Blood"},{"issue":"10","key":"647_CR27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"HJ Velde van de","year":"2007","unstructured":"van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92(10):1399\u20131406","journal-title":"Haematologica"},{"issue":"11","key":"647_CR28","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P et al (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025\u20133031","journal-title":"Blood"},{"issue":"3","key":"647_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.blre.2013.04.001","volume":"27","author":"A Palumbo","year":"2013","unstructured":"Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27(3):133\u2013142","journal-title":"Blood Rev"},{"issue":"1","key":"647_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.13243","volume":"169","author":"SK Girnius","year":"2015","unstructured":"Girnius SK, Lee S, Kambhampati S et al (2015) A phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol 169(1):36\u201343","journal-title":"Br J Haematol"},{"issue":"5","key":"647_CR31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjh.13238","volume":"169","author":"SY Ong","year":"2014","unstructured":"Ong SY, Ng HY, Surendran S et al (2014) Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Br J Haematol 169(5):754\u2013756","journal-title":"Br J Haematol"},{"issue":"2","key":"647_CR32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M et al (2013) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27(2):423\u2013429","journal-title":"Leukemia"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-016-0647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-016-0647-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-016-0647-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-016-0647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:40:10Z","timestamp":1559446810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-016-0647-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1007\/s12288-016-0647-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,27]]}}}